ArticleJournal of neuro-oncology2026
Extent of resection and perioperative neurological status as prognostic markers in glioblastoma: a population-based study.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spatial-temporal recurrence patterns of grade 4 glioma using deep learning integrated multiparametric MRI and molecular pathology.NPJ precision oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMaximal safe resection is the suggested standard for surgical treatment for patients with IDH-wildtype glioblastoma. Surgical safety is prioritized over radical extent of resection (EOR) because new neurological deficits are considered detrimental for survival. The aim of this study was to explore the combined impact of extent of resection and neurological status on survival in glioblastoma patients, using standardized tools for neurological function (neurological assessment in neuro-oncology (NANO scale) and extent of resection (RANO resect classification).
methodsPopulation-based study of all adult patients who underwent resection for newly diagnosed glioblastoma from 2019 to 2022 in a geographically defined region. EOR was evaluated according to the RANO resect classification. Neurological function was assessed using the NANO scale preoperatively, immediately after surgery, and before start of radiotherapy. Kaplan Meier survival analysis, chi-square and log-rank tests were used to compare groups.
resultsThe median overall survival (mOS) for 503 patients was 12.9 months. RANO resect class 1 was associated with significantly longer mOS compared to patients with RANO classes 2, 3, and 4 (21.0 vs. 14.8, 8.3, and 4.5 months, respectively; p < 0.01). Preoperatively neurologically intact patients (NANO-score 0) had a longer mOS, than patients with neurological deficits. Neither the postoperative NANO-score nor the change in the score impacted survival.
conclusionsBeing neurologically intact before surgery and supramaximal resection were independent, strong predictors of longer survival. Mild to moderate new postoperative neurological deficits did not impact mOS, suggesting that supramaximal resection may confer a survival benefit even when such deficits are induced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.